Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

P.A. Ascierto, G.V. Long, C. Robert, B. Brady, C. Dutriaux, A.M. Di Giacomo, L. Mortier, J.C. Hassel, P. Rutkowski, C. McNeil, E. Kalinka-Warzocha, K.J. Savage, M.M. Hernberg, C. Lebbé, J. Charles, C. Mihalcioiu, V. Chiarion-Sileni, C. Mauch, F. Cognetti, L. NyA. Arance, I.M. Svane, D. Schadendorf, H. Gogas, A. Saci, J. Jiang, J. Rizzo, V. Atkinson

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences